Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 16, 2023 07:00 ET | Source: Cabaletta Bio

Cabaletta Bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

– Company expecting Investigational New Drug (IND) clearance in the first half of 2023 for CABA-201, a 4-1BB-containing fully human CD19-CAR T cell therapy, with potential to generate initial clinical...
February 28, 2023 08:00 ET | Source: Cabaletta Bio

Cabaletta Bio to Present at the Cowen 43rd Annual Health Care Conference

PHILADELPHIA, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell...
January 05, 2023 08:00 ET | Source: Cabaletta Bio

Cabaletta Bio to Present at the 41st Annual J.P. Morgan Healthcare Conference

PHILADELPHIA, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell...
December 08, 2022 07:00 ET | Source: Cabaletta Bio

Cabaletta Bio Announces $35 Million Offering

PHILADELPHIA, Dec. 08, 2022 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (“Cabaletta” or the “Company”) (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the...
November 22, 2022 08:00 ET | Source: Cabaletta Bio

Cabaletta Bio to Present at the 5th Annual Evercore ISI HealthCONx Conference

PHILADELPHIA, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell...
November 10, 2022 07:00 ET | Source: Cabaletta Bio

Cabaletta Bio Reports Third Quarter 2022 Financial Results and Provides Business Update

PHILADELPHIA, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell...
October 11, 2022 07:00 ET | Source: Cabaletta Bio

Cabaletta Bio Announces CABA-201, a Newly Designed CD19-Targeting CAR T Cell Therapy Engineered to Address a Broad Range of Autoimmune Diseases

– Company has obtained exclusive worldwide license for a fully human CD19 binder with clinical tolerability data that support potential clinical development in autoimmune diseases – – CABA-201...
October 06, 2022 08:00 ET | Source: Cabaletta Bio

Cabaletta Bio to Present at the 29th Annual Congress of the European Society of Gene & Cell Therapy

PHILADELPHIA, Oct. 06, 2022 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of targeted cell therapies for...
September 26, 2022 08:00 ET | Source: Cabaletta Bio

Cabaletta Bio to Present at the Chardan 6th Annual Genetic Medicines Conference

PHILADELPHIA, Sept. 26, 2022 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of targeted cell therapies for...
September 10, 2022 07:00 ET | Source: Cabaletta Bio

Cabaletta Bio Presents New Interim Data from the DesCAARTes™ Phase 1 Trial at the 31st EADV Congress

PHILADELPHIA, Sept. 10, 2022 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of targeted cell therapies for...